Home
Country selector

PD-L1 Targeting

Immuno-oncology

PD-L1 targeting

The binding of PD-L1 to PD-1 results in T-cell suppression and inactivation. In cancer, PD-1/PD-L1 signaling serves as a mechanism for tumors to evade an immunologic response, thus promoting cancer progression and survival.1,2

Avelumab – anti-PD-L1 monoclonal antibody (mAb)

Avelumab is a fully human anti-PD-L1 IgG1 mAb.1

/content/dam/web/healthcare-hcp/oncology-hub/Article-PD-L1_Targeting-Fig--1.png
×
1
/content/dam/web/healthcare-hcp/oncology-hub/Article-PD-L1_Targeting-Fig--1.png
❮ ❯

/content/dam/web/healthcare-hcp/oncology-hub/Article-PD-L1_Targeting-Fig--1.png

Other targets under investigation

IgG1, immunoglobulin G1; mAb, monoclonal antibody; NK, natural killer; PD-1, programmed death-1; PD-L1, programmed death-ligand 1; TIGIT, T-cell immunoglobulin and ITIM domain.

  1. Heery CR, O'Sullivan-Coyne G, Madan RA, et al. Avelumab for metastatic or locally advanced previously treated solid tumours (JAVELIN Solid Tumor): a phase 1a, multicohort, dose-escalation trial. Lancet Oncol. 2017;18(5):587-598. 
  2. Akinleye A, Rasool Z. Immune checkpoint inhibitors of PD-L1 as cancer therapeutics. J Hematol Oncol. 2019;12(1):92.

GL-MULO-00162 | January 2024

This website is an international information resource intended only for Healthcare Professionals who are licensed to practice outside the U.S., Canada, and Puerto Rico.

The information on this site is intended for educational purposes.

Connect with us

Find the Healthcare Business of Merck on:

©2024 Merck KGaA, Darmstadt, Germany and/or its affiliates. All rights reserved. Registered address: Merck KGaA, Frankfurter Strasse 250, 64293 Darmstadt, Germany

GL-MULO-00155 | November 2023

Cookie Disclaimer

We use cookies so that we can offer you the best possible website experience. This includes cookies which are necessary for the operation of the website and to manage our corporate commercial objectives, as well as other cookies which are used solely for anonymous statistical purposes, for more comfortable website settings, or for the display of personalized content. You are free to decide which categories you would like to permit. Please note that depending on the settings you select, the full functionality of the website may no longer be available. You may review and change your choices at any time. Further information can be found in our Privacy Policy.

ACCEPT COOKIES
Your settings for the cookies

These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.

In order to continuously improve our website, we anonymously track data for statistical and analytical purposes. With these cookies we can, for example, track the number of visits or the impact of specific pages of our web presence and therefore optimize our content. 

These cookies allow us to provide more comfort for you. For example, previously searched products or services can be reloaded again after revisiting our website and you won’t need to enter all the details again. We can also detect if you need assistance with using our website and therefore offer you direct customer support.

These cookies are used to display personalized content matching your interests. We can display personalized and relevant services to ensure you are always up to date on related offers.

By clicking this link, you are leaving MerckGroupOncology.com. Please, note that this link will take you to a website оn which different Privacy Policy and Conditions may apply. Merck accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Continue
Go Back

Welcome to Merck Healthcare!

Help us direct you to the right information by selecting one of the following options:

I'm a Healthcare Professional

I'm NOT a Healthcare Professional